Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Organon & Co (OGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/27/2026: OGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.29
1 Year Target Price $9.29
| 0 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.95B USD | Price to earnings Ratio 10.43 | 1Y Target Price 9.29 |
Price to earnings Ratio 10.43 | 1Y Target Price 9.29 | ||
Volume (30-day avg) 7 | Beta 0.55 | 52 Weeks Range 6.15 - 15.93 | Updated Date 02/26/2026 |
52 Weeks Range 6.15 - 15.93 | Updated Date 02/26/2026 | ||
Dividends yield (FY) 4.18% | Basic EPS (TTM) 0.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-12 | When - | Estimate 0.76 | Actual 0.63 |
Profitability
Profit Margin 3.01% | Operating Margin (TTM) 16.19% |
Management Effectiveness
Return on Assets (TTM) 6.22% | Return on Equity (TTM) 30.56% |
Valuation
Trailing PE 10.43 | Forward PE 5.03 | Enterprise Value 11141023434 | Price to Sales(TTM) 0.3 |
Enterprise Value 11141023434 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 1.77 | Enterprise Value to EBITDA 7.44 | Shares Outstanding 259982912 | Shares Floating 259024484 |
Shares Outstanding 259982912 | Shares Floating 259024484 | ||
Percent Insiders 0.36 | Percent Institutions 77.87 |
Upturn AI SWOT
Organon & Co
Company Overview
History and Background
Organon & Co. (NYSE: OGN) was spun off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. It is a global healthcare company focused on women's health. The company inherited a portfolio of established brands from Merck, along with a legacy of innovation in women's health dating back to the original Organon, which was acquired by Schering-Plough, and subsequently by Merck.
Core Business Areas
- Women's Health: Organon's primary focus is on improving the health and well-being of women. This includes a broad range of products across reproductive health (contraception, fertility), women's oncology, and biosimil products. The company aims to provide solutions throughout a woman's life.
- Cardiovascular & Metabolic: Organon also offers select products in cardiovascular and metabolic diseases, leveraging its established global reach.
- Biosimil Products: A significant part of Organon's portfolio includes biosimilar products, providing more affordable alternatives to complex biologic medicines across various therapeutic areas.
Leadership and Structure
Organon is led by a dedicated management team with extensive experience in the pharmaceutical industry. The company operates globally with a decentralized structure that allows for regional focus while maintaining centralized strategic direction.
Top Products and Market Share
Key Offerings
- Market Share (%): 15.2
- Product Name 1: Nexplanon (etonogestrel implant) - A long-acting reversible contraceptive implant. It is a leading product in the global contraceptive market. Competitors include other LARC methods like IUDs (e.g., Mirena by Bayer) and other implantable contraceptives.
- Revenue (USD millions): 1200
- Users (millions): 5.8
- Market Share (%): 8.5
- Product Name 2: Marvelon/Desogestrel - Oral contraceptive pills. A widely used category with numerous competitors from various pharmaceutical companies globally.
- Revenue (USD millions): 650
- Users (millions): 3.5
- Market Share (%): 10.1
- Product Name 3: Zarzio (filgrastim biosimilar) - A biosimilar to Neupogen, used to stimulate the production of white blood cells. Competitors include other filgrastim biosimil manufacturers (e.g., Pfizer, Teva) and the originator product (Neupogen).
- Revenue (USD millions): 400
- Users (millions): 1.2
- Market Share (%): 7.2
- Product Name 4: NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) - A vaginal ring for contraception. Competitors include other hormonal contraceptives and LARC methods.
- Revenue (USD millions): 350
- Users (millions): 2
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the women's health and biosimil segments, is characterized by ongoing innovation, evolving regulatory landscapes, and increasing demand for accessible and affordable healthcare solutions. The women's health market is experiencing growth driven by an aging global population, increased awareness of women's health issues, and demand for advanced reproductive health technologies. The biosimil market is expanding as more biologic drugs go off-patent, creating opportunities for cost-effective alternatives.
Positioning
Organon is positioned as a pure-play global healthcare company dedicated to women's health, leveraging a strong portfolio of established brands and a growing biosimilar business. Its competitive advantages include a significant global commercial infrastructure inherited from Merck, a deep understanding of the women's health market, and a strategic focus on this underserved segment. The company's commitment to increasing access to its products worldwide is a key differentiator.
Total Addressable Market (TAM)
The global women's health market is substantial and projected to grow significantly, with estimates varying by segment. The contraceptive market alone is valued in the tens of billions of USD globally. The biosimilar market is also a multi-billion dollar industry. Organon is well-positioned to capture a significant share of this TAM, particularly within its core therapeutic areas of contraception and biosimil generics.
Upturn SWOT Analysis
Strengths
- Strong established portfolio of women's health products.
- Global commercial infrastructure and reach.
- Focus on a dedicated and growing market segment (women's health).
- Experienced management team with pharmaceutical expertise.
- Growing biosimilar portfolio offering cost-effective solutions.
Weaknesses
- Reliance on a few key established products.
- Limited pipeline of novel, high-growth assets compared to R&D-heavy pharma giants.
- Potential for pricing pressures in established markets.
- Spin-off from a larger entity may present integration challenges.
Opportunities
- Expansion into emerging markets with unmet women's health needs.
- Development and commercialization of new biosimil products.
- Strategic partnerships and acquisitions to bolster pipeline and market presence.
- Increased focus on digital health solutions for women.
- Leveraging existing infrastructure for new product launches.
Threats
- Increasing competition from both branded and generic manufacturers.
- Regulatory changes and pricing controls in key markets.
- Patent expirations on key products leading to generic erosion.
- Shifts in healthcare provider and patient preferences.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Bayer AG (BAYZF)
- Gilead Sciences, Inc. (GILD)
- Amgen Inc. (AMGN)
- Novartis AG (NVS)
Competitive Landscape
Organon operates in a highly competitive pharmaceutical landscape. Its advantages lie in its focused women's health strategy and established global network. However, it faces significant competition from large pharmaceutical companies with extensive R&D pipelines and broad therapeutic portfolios. The biosimilar market is also increasingly crowded with established players and new entrants.
Growth Trajectory and Initiatives
Historical Growth: Since its spin-off, Organon has focused on maintaining the performance of its legacy products and expanding its biosimilar offerings. Growth has been steady, driven by demand for its key women's health products and the increasing penetration of its biosimil portfolio. The company has also engaged in strategic partnerships to enhance its market presence.
Future Projections: Analyst projections for Organon suggest moderate revenue growth, driven by continued strength in its core women's health portfolio and the expansion of its biosimilar business. Investments in R&D and potential new product launches are expected to contribute to future growth. The company is expected to focus on expanding its footprint in key international markets.
Recent Initiatives: Organon has actively pursued strategic partnerships and collaborations to expand its commercial reach and pipeline. Initiatives include expanding access to its contraceptive products, developing new biosimilar candidates, and exploring innovative digital health solutions for women. The company has also been focused on optimizing its operational structure post-spin-off.
Summary
Organon & Co. is a focused pharmaceutical company with a strong foundation in women's health and a growing biosimilar business. Its established product portfolio provides stable revenue, while its strategic focus on a key demographic presents significant growth potential. The company needs to carefully manage pricing pressures and competitive threats, while continuing to invest in its biosimilar pipeline and exploring new market opportunities to ensure long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Organon & Co. Investor Relations
- Company Annual Reports (10-K)
- Pharmaceutical Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is an aggregated analysis based on publicly available information and does not constitute financial advice. Market share data and revenue figures are estimates and can vary. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organon & Co
Exchange NYSE | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2021-06-02 | Interim CEO & Executive VP and Head of Manufacturing & Supply Mr. Joseph T. Morrissey Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 10000 | Website https://www.organon.com |
Full time employees 10000 | Website https://www.organon.com | ||
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.